Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United Sta…
An institutional-grade, numbers-driven thesis on AUPH — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Aurinia Pharmaceuticals Inc. (AUPH) 73/100 with a 12-month base-case forecast of $16.00 — +3.4% versus the current price of $15.47. Aurinia Pharmaceuticals Inc. trades at $15.47 in the Healthcare sector, with a market capitalisation of $1.99B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for AUPH is $16.00, implying +3.4% versus the current price. The model's 12-month scenario range runs from $21.68 (bear) to $29.63 (bull), with a base case of $24.40.
On the fundamentals, Aurinia Pharmaceuticals shows a P/E of 6.5, trailing revenue of $283.1M, revenue growth of +20.4% YoY. This page also tracks AUPH's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
AUPH currently carries a TradersQuant composite score of 73/100, which we read as a strong composite signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $16.00 implies +3.4% from $15.47. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for AUPH is $16.00, about +3.4% versus the latest price of $15.47. Consensus is based on 15 analysts.
TradersQuant's 12-month model forecast for AUPH is a base case of $24.40, ranging from $21.68 (bear) to $29.63 (bull), an expected return of +57.7%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for AUPH over the next 12 months is $24.40 in the base case (bear $21.68, bull $29.63), versus today's price of $15.47. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for AUPH — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates AUPH's fair value at $16.00, implying +3.4% of expected upside versus the current price.
Aurinia Pharmaceuticals does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
